Talis Biomedical Corp
TLISDelisted Sep 20, 2024- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001584751
Talis Biomedical Corp was delisted on Sep 20, 2024; its insiders filed their last Form 4 on Sep 9, 2024; 18 institutions reported holding it in 13F filings for Q2 2024, worth $6.84M in total; Greenlight Capital was the only superinvestor holding it.
13F holders, Q4 2023
Institutional positions in Talis Biomedical Corp as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- −1 vs. Q3 2023
- Shares held
- 796.6K
- +55.7K (+7.5%) vs. Q3 2023
- Total value
- $5.93M
- +$1.66M (+38.8%) vs. Q3 2023
- New holders
- 2
- 7 more added
- Sold out
- 3
- 3 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TLIS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 1 | $26 |
| Q3 2024 | 2 | $460.4K |
| Q2 2024 | 18 | $6.84M |
| Q1 2024 | 18 | $6.93M |
| Q4 2023 | 18 | $5.93M |
| Q3 2023 | 19 | $4.27M |
| Q2 2023 | 22 | $5.27M |
| Q1 2023 | 22 | $5.76M |
| Q4 2022 | 27 | $5.60M |
| Q3 2022 | 29 | $8.59M |
| Q2 2022 | 35 | $12.1M |
| Q1 2022 | 45 | $23.6M |
| Q4 2021 | 47 | $70.2M |
| Q3 2021 | 38 | $119.2M |
| Q2 2021 | 43 | $184.0M |
| Q1 2021 | 45 | $269.0M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Talis Biomedical Corp; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 508,323 | $3.79M | 0.04% | 00.0% | Unchanged |
| Greenlight Capital Inc | 149,052 | $1.11M | 0.05% | 00.0% | Unchanged |
| BML Capital Management, LLC | 42,743 | $318.4K | 0.25% | +42,743 | New |
| Vanguard Group Inc | 31,013 | $231.0K | 0.00% | +294+1.0% | Added |
| Susquehanna International Group, LLP | 15,571 | $116.0K | 0.00% | +3,405+28.0% | Added |
| Prelude Capital Management, LLC | 14,928 | $111.2K | 0.01% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 11,280 | $84.1K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 10,432 | $77.7K | 0.00% | +5,506+111.8% | Added |
| Citadel Advisors LLC | 10,024 | $74.7K | 0.00% | +10,024 | New |
| Citigroup Inc | 1,624 | $12.1K | 0.00% | −3,643−69.2% | Reduced |
| Tower Research Capital LLC (TRC) | 988 | $7.36K | 0.00% | +208+26.7% | Added |
| Morgan Stanley | 371 | $2.76K | 0.00% | −1,890−83.6% | Reduced |
| UBS Group AG | 127 | $946 | 0.00% | +36+39.6% | Added |
| Advisor Group Holdings, Inc. | 105 | $782 | 0.00% | −67−39.0% | Reduced |
| Larson Financial Group LLC | 14 | $104 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 13 | $97 | 0.00% | +1+8.3% | Added |
| Qube Research & Technologies Ltd | 2 | $15 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 2 | $15 | 0.00% | +1+100.0% | Added |
| Deutsche Bank AG | 0 | $0 | 0.00% | −600−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −281−100.0% | Sold out |
| New England Capital Financial Advisors LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |